Avista Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Avista Therapeutics, Inc.
Roche said it remains deeply committed to the therapeutic area and highlighted a broad clinical pipeline at a virtual investor event.
During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.
- Gene Therapy, Cell Therapy
Drug Discovery Technologies
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.